FDA to weigh easing limits on unproven peptides promoted by RFK Jr. BPC 157: What Research Shows (and What It Doesn't) Meeting Point Health This is one of the biggest peptide regulatory shifts in years. And it's just getting started. The FDA has taken its first step toward reversing its 2023 stance, removing 12 peptides from GOP lawmakers ask RFK Jr. to make FDA unleash risky peptides like BPC 157 The Niche